A Study to Determine Appropriate Dosage for Vapor Therapy and Other Ablative Therapies to Treat Cancerous Prostate and Kidney Tissue

Overview

About this study

The study objectives are to determine the appropriate dosage for vapor therapy and other ablative therapies to treat cancerous prostate and kidney tissue.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects with the ability to understand and consent to releasing their extirpated prostate or kidney for use in this study, if required by the site.

Prostate Tissue:

  • Prostates with a confirmed biopsy demonstrating adenocarcinoma removed via a radical prostatectomy.
  • Prostates with biopsy confirmed recurrent adenocarcinoma removed via a salvage radical prostatectomy.
  • Prostates with or without cancer that have been removed via a radical cystoprostatectomy or pelvic exenteration.

Kidney Tissue:

  • Kidneys removed via a total or partial nephrectomy – no enucleations will be used.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lance Mynderse, M.D.

Contact us for the latest status

Contact information:

Lance Mynderse M.D.

(507) 538-0484

Mynderse.Lance@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20319143

Mayo Clinic Footer